Esperion Therapeutis.Inc. buy HC Wainwright
Summary
This prediction is currently active. The prediction currently has a performance of 21.42%. This prediction currently runs until 02.10.25. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | 21.42% |
iShares Core DAX® | -1.114% |
iShares Nasdaq 100 | 1.816% |
iShares Nikkei 225® | 2.113% |
iShares S&P 500 | 2.038% |
Comments by HC_Wainwright for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by HC_Wainwright for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
12.08.24
12.08.25
04.10.24
Esperion Therapeutis.Inc.
28.06.24
28.06.25
04.10.24
Esperion Therapeutis.Inc.
21.05.24
21.05.25
04.10.24
Esperion Therapeutis.Inc.
08.05.24
08.05.25
04.10.24
Esperion Therapeutis.Inc.
25.03.24
25.03.25
04.10.24
Esperion Therapeutis.Inc.
28.02.24
28.02.25
04.10.24
Esperion Therapeutis.Inc.
13.11.23
13.11.24
04.10.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
29.08.24
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24